Core Viewpoint - The stock of Kedi Group (02487) has risen over 10%, currently trading at 7.19 HKD, with a transaction volume of 5.7763 million HKD, following the announcement of the commercialization of its innovative products [1] Product Launch - Kedi Group has officially launched the first batch of its original imported 4% Minocycline Hydrochloride Foam (Anzqing®) from its Wuxi factory, which is the world's first and only topical 4% Minocycline Hydrochloride foam for treating moderate to severe inflammatory lesions of acne in patients aged 9 and above [1] - On October 17, Kedi Group announced the commercialization of its original imported Finasteride Spray (Finjuve®), with the first batch being dispatched from Shanghai Pharmaceutical International Supply Chain Co., Ltd. to various locations across the country, officially starting sales in China on October 20 [1] Market Position and Growth Potential - According to Caitong Securities, Kedi Group is emerging as a new star in the field of dermatological treatments, with its two core products possessing strong differentiation advantages, which are expected to drive performance growth as commercialization progresses [1] - According to Kaiyuan Securities, the company has established a diversified product portfolio covering hair diseases, skin care, and medical aesthetics, indicating a promising growth space with the acceleration of product pipeline commercialization [1]
港股异动 | 科笛-B(02487)涨超10% 外用米诺环素泡沫剂、非那雄胺喷雾剂国内开启销售